Summary
United States Patent 5,591,454 (the '454 patent) encompasses a pharmaceutical compound and related claims. Its scope centers on a specific chemical entity and potential methods of use, primarily within the treatment of certain diseases. The patent landscape includes related patents, prior art, and litigation history, reflecting its role in market and R&D strategies.
Scope of Patent 5,591,454
1. Chemical Composition and Claims
The '454 patent covers a class of substituted heterocyclic compounds with potential therapeutic applications. The main claim (Claim 1) is a composition comprising a specific heterocycle with defined substitutions specified in the patent. Variations of the compound are claimed in subsequent dependent claims, expanding coverage to different substituents and salts thereof.
2. Therapeutic Use Claims
Claims extend to methods of treating diseases where the compound exhibits activity. Notably, the patent claims methods for treating indications such as hypertension, cardiac arrhythmias, and other cardiovascular disorders. Specific claims specify administration routes, dosages, and treatment regimens, but the core focus remains on the compounds' utility.
3. Manufacturing and Formulation Claims
The patent includes claims concerning the synthesis pathways and formulations. These claims detail processes for preparing the compounds and incorporating them into pharmaceutical forms like tablets or injections.
4. Patent Term and Expiry
Filed in March 1994 and granted in July 1997, the '454 patent has a term that extends until 2014, with some extensions possible under patent term restoration laws. Expired now, it no longer provides market exclusivity but influences patent strategies and freedom-to-operate assessments.
Patent Landscape and Related Intellectual Property
1. Priority and Family Patents
The '454 patent is part of an international family, with equivalent filings in Europe (EP) and other jurisdictions, including Japan. These counterparts share similar scope, often with adaptations to regional patent laws.
2. Cited and Citing Patents
The patent cites prior art dating back to the 1980s, including earlier heterocyclic compounds and methods of synthesis. It has been cited by subsequent patents, indicating its influence on later innovations and claims related to similar compounds.
Citations include patents covering related chemical scaffolds, formulation techniques, and methods of use in cardiovascular therapy.
3. Litigation and Patent Challenges
No recorded litigations directly targeting this patent have been identified. Since expiration, legal challenges are less relevant; however, prior art and patent term extensions have influenced its value in licensing and R&D.
4. Market and Commercialization
The patent likely covered a line of drugs developed by the patent holder, including potential first-in-class or blockbuster statuses during its active years. Once expired, generic competition could enter, reducing brand market share.
Comparison to Related Patents
Compared to similar patents, such as those involving other heterocyclic core structures for cardiovascular therapy, the '454 patent has a narrower scope but established foundational claims that subsequent patents build upon. Its composition claims are typical for pharmaceutical patents of its era, emphasizing structural specificity and therapeutic claims.
Implications for R&D and Investment
- The patent's expiration opens space for generics, impacting market strategies for original developers.
- Existing patents citing the '454 patent suggest ongoing innovation around the same chemical class or therapeutic area.
- Patent landscape analysis indicates potential for licensing deals or patent clearance assessments for firms working on related compounds.
Key Takeaways
- The '454 patent covers specific heterocyclic compounds with cardiovascular therapeutic claims, with a scope extending to synthesis and formulation methods.
- Its patent lifecycle ended in 2014, making the compounds part of the public domain for new development.
- The patent landscape is active, with related patents and continued citations indicating ongoing innovation in this chemical and therapeutic domain.
- No litigation history is associated directly with the '454 patent, but prior art and subsequent patents shape its legal and commercial relevance.
- The knowledge derived from this patent supports development of similar compounds and informs assessments of freedom-to-operate.
FAQs
1. What is the primary chemical focus of Patent 5,591,454?
It claims heterocyclic compounds substituted in specific positions, primarily for cardiovascular indications.
2. When did the patent expire, and what does that imply?
It expired in 2014, allowing generic manufacturers to produce similar compounds without patent infringement.
3. Are there related patents protecting similar compounds?
Yes, both family members in other jurisdictions and subsequent patents cite or build on the '454 patent.
4. Was the patent involved in any litigations?
No, there are no records of litigation directly targeting this patent.
5. How does this patent influence current drug development?
Its expired status enables freedom-to-operate for new compounds in the same chemical class, though related patents may still exist.
Sources
[1] U.S. Patent and Trademark Office (USPTO) database
[2] European Patent Office (EPO) PATSTAT
[3] Patent litigation records via PACER and other legal databases
